血友病A和抑制剂患者Emicizumab预防前后拔牙的独特比较

IF 0.7 Q4 DENTISTRY, ORAL SURGERY & MEDICINE
Case Reports in Dentistry Pub Date : 2025-05-22 eCollection Date: 2025-01-01 DOI:10.1155/crid/8128415
Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa
{"title":"血友病A和抑制剂患者Emicizumab预防前后拔牙的独特比较","authors":"Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa","doi":"10.1155/crid/8128415","DOIUrl":null,"url":null,"abstract":"<p><p>Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII. Emicizumab has been licenced for the prevention of bleeding in patients with haemophilia A with inhibitors and has demonstrated an 87% reduction in the annualised bleeding rate compared with on-demand therapy in patients with haemophilia A with inhibitors. Emicizumab is approved not only for patients with inhibitors but also for those without inhibitors. However, no reports exist on intraindividual comparisons of perioperative management of tooth extraction before and after emicizumab prophylaxis. This case report describes the perioperative management of similar tooth extractions in the same patient with haemophilia A with inhibitors before and after the initiation of emicizumab. This report provides a unique opportunity for intraindividual comparison of the usage of bypassing agents, postextraction bleeding, and medical costs with and without emicizumab. Furthermore, our report also supports the hypothesis that emicizumab is superior in preventing postoperative bleeding complications.</p>","PeriodicalId":46841,"journal":{"name":"Case Reports in Dentistry","volume":"2025 ","pages":"8128415"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122152/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors.\",\"authors\":\"Miki Zaizen, Takahiro Yagyuu, Sachiko Yata, Hiroshi Nakamura, Mitsuhiko Imada, Nobuhiro Yamakawa\",\"doi\":\"10.1155/crid/8128415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII. Emicizumab has been licenced for the prevention of bleeding in patients with haemophilia A with inhibitors and has demonstrated an 87% reduction in the annualised bleeding rate compared with on-demand therapy in patients with haemophilia A with inhibitors. Emicizumab is approved not only for patients with inhibitors but also for those without inhibitors. However, no reports exist on intraindividual comparisons of perioperative management of tooth extraction before and after emicizumab prophylaxis. This case report describes the perioperative management of similar tooth extractions in the same patient with haemophilia A with inhibitors before and after the initiation of emicizumab. This report provides a unique opportunity for intraindividual comparison of the usage of bypassing agents, postextraction bleeding, and medical costs with and without emicizumab. Furthermore, our report also supports the hypothesis that emicizumab is superior in preventing postoperative bleeding complications.</p>\",\"PeriodicalId\":46841,\"journal\":{\"name\":\"Case Reports in Dentistry\",\"volume\":\"2025 \",\"pages\":\"8128415\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122152/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Dentistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/crid/8128415\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dentistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crid/8128415","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

血友病A是一种由因子VIII缺乏引起的遗传性x连锁出血性疾病;大约30%的A型血友病患者产生抗因子VIII的抑制剂。Emicizumab已被批准用于预防A型血友病患者联合抑制剂的出血,与A型血友病联合抑制剂的按需治疗相比,Emicizumab已证明年化出血率降低87%。Emicizumab不仅被批准用于有抑制剂的患者,也被批准用于无抑制剂的患者。然而,目前还没有关于emicizumab预防前后拔牙围手术期管理的个体比较报告。本病例报告描述了在开始使用emicizumab之前和之后使用抑制剂的同一血友病A患者类似拔牙的围手术期管理。本报告提供了一个独特的机会,对使用和不使用emicizumab的旁路药物的使用、提取后出血和医疗费用进行个体比较。此外,我们的报告也支持emicizumab在预防术后出血并发症方面具有优势的假设。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Unique Comparison of Tooth Extraction Before and After Emicizumab Prophylaxis in a Patient With Haemophilia A and Inhibitors.

Haemophilia A is an inherited X-linked bleeding disorder caused by Factor VIII deficiency; approximately 30% of the patients with haemophilia A develop inhibitors against Factor VIII. Emicizumab has been licenced for the prevention of bleeding in patients with haemophilia A with inhibitors and has demonstrated an 87% reduction in the annualised bleeding rate compared with on-demand therapy in patients with haemophilia A with inhibitors. Emicizumab is approved not only for patients with inhibitors but also for those without inhibitors. However, no reports exist on intraindividual comparisons of perioperative management of tooth extraction before and after emicizumab prophylaxis. This case report describes the perioperative management of similar tooth extractions in the same patient with haemophilia A with inhibitors before and after the initiation of emicizumab. This report provides a unique opportunity for intraindividual comparison of the usage of bypassing agents, postextraction bleeding, and medical costs with and without emicizumab. Furthermore, our report also supports the hypothesis that emicizumab is superior in preventing postoperative bleeding complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Case Reports in Dentistry
Case Reports in Dentistry DENTISTRY, ORAL SURGERY & MEDICINE-
CiteScore
1.40
自引率
12.50%
发文量
107
审稿时长
14 weeks
期刊介绍: Case Reports in Dentistry is a peer-reviewed, Open Access journal that publishes case reports and case series in all areas of dentistry, including periodontal diseases, dental implants, oral pathology, as well as oral and maxillofacial surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信